GO:0050731 positive regulation of peptidyl-tyrosine phosphorylation: Signaling Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0050731 describes any process that activates or increases the frequency, rate or extent of peptidyl-tyrosine phosphorylation, a central post-translational modification in cell signaling.
• Peptidyl-tyrosine phosphorylation is catalyzed by protein tyrosine kinases and reversed by protein tyrosine phosphatases, making it a reversible switch in signal transduction.
• Dysregulation of this process is implicated in cancer, inflammatory diseases, and metabolic disorders, as shown by bioinformatics and network pharmacology studies.
• Key genes involved include receptor tyrosine kinases such as EGFR, and non-receptor kinases such as SRC and JAK2, which are frequently identified as hub genes in disease datasets.
• Modern research uses CRISPR knockout, point mutation, knock-in, and overexpression models to dissect causal roles of specific tyrosine phosphorylation events.
• Bioinformatics and network pharmacology approaches are widely used to predict and validate regulators of peptidyl-tyrosine phosphorylation in disease contexts.
Description
GO:0050731, positive regulation of peptidyl-tyrosine phosphorylation, is a biological process Gene Ontology term that captures any mechanism that increases the phosphorylation of tyrosine residues on proteins. This modification is a cornerstone of intracellular signal transduction, enabling cells to respond to growth factors, cytokines, and hormones. Because tyrosine phosphorylation is reversible and tightly controlled, its positive regulation is critical for normal development and tissue homeostasis. Researchers study this term to understand how signaling cascades are amplified or sustained in diseases such as cancer and inflammation. The term is defined in QuickGO as any process that activates or increases the frequency, rate or extent of the phosphorylation of peptidyl-tyrosine. It encompasses the action of protein tyrosine kinases, adaptor proteins, and regulatory subunits that enhance kinase activity or substrate accessibility. In this article, we integrate authoritative GO data with real PubMed literature to provide a research-grade overview of the genes, mechanisms, and experimental models relevant to GO:0050731.
positive regulation of peptidyl-tyrosine phosphorylation At A Glance
| GO ID | GO:0050731 |
|---|---|
| GO term | positive regulation of peptidyl-tyrosine phosphorylation |
| Ontology | biological_process |
| Synonym | activation of peptidyl-tyrosine phosphorylation; stimulation of peptidyl-tyrosine phosphorylation; up regulation of peptidyl-tyrosine phosphorylation; up-regulation of peptidyl-tyrosine phosphorylation; upregulation of peptidyl-tyrosine phosphorylation |
| Major function | Enhances tyrosine phosphorylation of proteins, a key post-translational modification in signal transduction |
| Related kinases | Protein tyrosine kinases such as EGFR, SRC, JAK2 |
| Related phosphatases | Protein tyrosine phosphatases that counteract the modification |
| Disease relevance | Cancer, inflammatory diseases, metabolic disorders |
| Research methods | Bioinformatics, network pharmacology, CRISPR models, phosphoproteomics |
What Is GO:0050731?
In simple terms, GO:0050731 refers to the biological processes that boost the addition of phosphate groups to tyrosine residues on proteins. According to QuickGO, it is any process that activates or increases the frequency, rate or extent of the phosphorylation of peptidyl-tyrosine. This definition includes the direct activation of tyrosine kinases, the recruitment of substrates, and the inhibition of phosphatases that would otherwise remove the phosphate. It is a positive regulatory process, meaning it enhances rather than reduces tyrosine phosphorylation.
Why Is positive regulation of peptidyl-tyrosine phosphorylation Important in Cell Biology?
Positive regulation of peptidyl-tyrosine phosphorylation is fundamental to how cells transmit signals from the surface to the nucleus, controlling proliferation, differentiation, migration, and survival. Its dysregulation is a hallmark of many cancers, where hyperactive tyrosine kinases drive oncogenesis. Inflammatory and metabolic diseases also involve aberrant tyrosine phosphorylation, making this process a prime therapeutic target. Understanding its regulators is essential for developing kinase inhibitors and other targeted therapies.
• Central to growth factor and cytokine signaling pathways.
• Frequently dysregulated in cancer, contributing to tumor growth and survival.
• Involved in immune cell activation and inflammatory responses.
• Target of approved and investigational tyrosine kinase inhibitors.
• Key to understanding mechanisms of drug resistance in cancer therapy.
• Plays a role in metabolic disorders such as diabetes and nephrotic syndrome.
• Essential for neuronal development and synaptic plasticity.
• Regulated by protein tyrosine phosphatases, offering additional therapeutic targets.
• Studied using bioinformatics to identify biomarkers and hub genes.
• CRISPR-based models enable causal validation of specific phosphorylation events.
What Happens During positive regulation of peptidyl-tyrosine phosphorylation?
Activation of Protein Tyrosine Kinases
In simple terms: Kinases are enzymes that add phosphate groups; activating them is the first step in boosting tyrosine phosphorylation.
Positive regulation often begins with the activation of protein tyrosine kinases, either through ligand binding to receptor tyrosine kinases or through intracellular signals that activate non-receptor kinases. For example, growth factor binding induces receptor dimerization and autophosphorylation, which increases kinase activity and creates docking sites for downstream proteins. This activation can be amplified by adaptor proteins and scaffolding molecules that bring kinases into proximity with their substrates.
Recruitment of Substrates and Adaptors
In simple terms: Bringing the right proteins together makes phosphorylation more efficient.
Once kinases are active, positive regulation involves the recruitment of specific substrates and adaptor proteins to the signaling complex. Adaptors such as GRB2 and SHC contain SH2 domains that bind phosphotyrosine motifs, facilitating the assembly of signaling hubs. This spatial organization increases the local concentration of substrates, enhancing the rate and extent of tyrosine phosphorylation.
Inhibition of Protein Tyrosine Phosphatases
In simple terms: Phosphatases remove phosphate groups; blocking them tips the balance toward more phosphorylation.
Because tyrosine phosphorylation is reversible, positive regulation can also occur by inhibiting protein tyrosine phosphatases (PTPs) that would otherwise dephosphorylate substrates. For instance, reactive oxygen species can oxidize the catalytic cysteine of PTPs, transiently inactivating them and thereby enhancing phosphorylation. This mechanism is particularly important in immune signaling and cancer.
Feedback and Amplification Loops
In simple terms: Signals can be amplified by positive feedback, making the response stronger and longer.
Positive regulation is often reinforced by feedback loops where downstream kinases activate upstream components or inhibit phosphatases. For example, ERK can phosphorylate and activate upstream receptors or adaptors, creating a positive feedback loop that sustains tyrosine phosphorylation. Such loops are critical for switch-like responses in cell fate decisions.
Key Genes Involved in GO:0050731 positive regulation of peptidyl-tyrosine phosphorylation
The following genes and proteins are central to the positive regulation of peptidyl-tyrosine phosphorylation, as supported by the cited literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| EGFR | Receptor tyrosine kinase; autophosphorylation upon ligand binding | Frequently mutated in cancers; target of inhibitors |
| SRC | Non-receptor tyrosine kinase; phosphorylates many substrates | Oncogene; involved in proliferation and migration |
| JAK2 | Non-receptor kinase; mediates cytokine signaling | Mutated in myeloproliferative disorders |
| STAT3 | Transcription factor activated by JAK2 phosphorylation | Key downstream effector in inflammation and cancer |
| PTPN11 | Protein tyrosine phosphatase; counteracts phosphorylation | Mutated in Noonan syndrome and leukemia |
| GRB2 | Adaptor protein; binds phosphotyrosine motifs | Links receptor kinases to RAS-MAPK pathway |
| SHC1 | Adaptor protein; recruits GRB2 | Involved in growth factor signaling |
| PIK3CA | Catalytic subunit of PI3K; activated by tyrosine phosphorylation | Oncogene in many cancers |
| AKT1 | Serine/threonine kinase downstream of PI3K | Promotes survival and growth |
| MAPK1 | ERK2; downstream of RAS-MAPK | Regulates proliferation and differentiation |
| PTK2 | Focal adhesion kinase; regulates cell adhesion | Implicated in cancer invasion |
| LCK | Src-family kinase; T-cell receptor signaling | Target in autoimmune diseases |
| SYK | Spleen tyrosine kinase; immune receptor signaling | Involved in allergy and autoimmunity |
| ZAP70 | Tyrosine kinase; T-cell activation | Mutations cause immunodeficiency |
| VAV1 | Guanine nucleotide exchange factor; activated by tyrosine phosphorylation | Regulates cytoskeleton and immune responses |
| CRK | Adaptor protein; binds phosphotyrosine | Involved in cell migration |
| NCK1 | Adaptor protein; links receptors to actin dynamics | Role in cytoskeletal reorganization |
How Is positive regulation of peptidyl-tyrosine phosphorylation Regulated?
The positive regulation of peptidyl-tyrosine phosphorylation is itself tightly regulated by multiple mechanisms. Protein tyrosine phosphatases (PTPs) provide a counterbalance by removing phosphate groups, and their inhibition or downregulation enhances phosphorylation. Kinase activity can be modulated by phosphorylation, ubiquitination, or interaction with regulatory subunits. Additionally, scaffold proteins and lipid second messengers localize kinases and substrates to specific subcellular compartments, ensuring spatial specificity. In disease, mutations in kinases or phosphatases can constitutively activate or inactivate these regulatory circuits.
positive regulation of peptidyl-tyrosine phosphorylation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| EGFR | Non-small cell lung cancer | Knockout and point mutation models to test inhibitor resistance |
| JAK2 | Myeloproliferative neoplasms | Knock-in of JAK2 V617F mutation |
| SRC | Colorectal cancer | Overexpression and knockout in cell lines |
| PTPN11 | Noonan syndrome and leukemia | Point mutation knock-in in hematopoietic cells |
| SYK | Autoimmune diseases | Knockout in immune cell models |
Cancer
Dysregulated positive regulation of peptidyl-tyrosine phosphorylation is a hallmark of many cancers. Activating mutations in receptor tyrosine kinases such as EGFR or non-receptor kinases like SRC lead to constitutive phosphorylation and uncontrolled proliferation. Bioinformatics analyses have identified hub genes related to tyrosine phosphorylation as biomarkers in bladder cancer and glioma. Targeting these pathways with kinase inhibitors is a major therapeutic strategy.
Inflammatory and Immune Disorders
Tyrosine phosphorylation is essential for immune cell activation. Positive regulators such as JAK2 and SYK are critical in cytokine and antigen receptor signaling, and their overactivation contributes to autoimmune diseases and chronic inflammation. Network pharmacology studies have highlighted natural compounds that modulate these pathways for therapeutic benefit.
Metabolic and Renal Diseases
Altered tyrosine phosphorylation is observed in metabolic disorders such as nephrotic syndrome. A study on Danggui-Shaoyao-San showed that its regulation of the metabolome involves tyrosine phosphorylation-related pathways. This suggests that positive regulators could be targeted in metabolic and renal diseases.
From positive regulation of peptidyl-tyrosine phosphorylation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a kinase reduce tyrosine phosphorylation? | CRISPR knockout cell line |
| Does a specific mutation activate a kinase? | Point mutation knock-in |
| Does a phosphotyrosine site recruit adaptors? | Knock-in of tyrosine-to-phenylalanine mutant |
| Does overexpression drive oncogenic signaling? | Overexpression cell model |
| Can a drug inhibit a kinase in vivo? | Xenograft with knockout or mutant cells |
| What are the downstream effectors? | Phosphoproteomics and RNA-seq |
How to Study the positive regulation of peptidyl-tyrosine phosphorylation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Phosphoproteomics | Global tyrosine phosphorylation sites | Identify substrates and pathways |
| Western blot with anti-phosphotyrosine | Overall tyrosine phosphorylation levels | Validate kinase activation |
| CRISPR knockout screen | Genes required for phosphorylation | Discover novel regulators |
| Network pharmacology | Predicted interactions and pathways | Drug mechanism studies |
| FRET biosensors | Real-time kinase activity | Live-cell imaging |
| RNA-seq | Transcriptional changes | Downstream effects |
| Molecular docking | Binding affinity of inhibitors | Drug design |
| Immunoprecipitation | Protein-protein interactions | Complex composition |
Phosphoproteomics
Mass spectrometry-based phosphoproteomics allows global profiling of tyrosine phosphorylation sites. This method can quantify changes in response to kinase activation or inhibition, identifying direct substrates and pathways. It is often combined with bioinformatics to map signaling networks.
Bioinformatics and Network Pharmacology
Computational approaches integrate gene expression, mutation, and interaction data to predict key regulators of tyrosine phosphorylation. Studies have used these methods to identify biomarkers in bladder cancer and to elucidate mechanisms of natural compounds. Network pharmacology is particularly useful for predicting multi-target effects.
CRISPR Screening
Genome-wide CRISPR knockout or activation screens can identify genes that positively regulate tyrosine phosphorylation. Cells are selected for a phenotype such as drug resistance or reporter activation, and enriched sgRNAs reveal candidate regulators. This unbiased approach is powerful for discovering novel components.
Imaging and Proximity Labeling
Fluorescence resonance energy transfer (FRET) biosensors and proximity labeling techniques such as BioID can visualize and identify tyrosine phosphorylation events in live cells. These methods provide spatial and temporal resolution, complementing biochemical assays.
How CRISPR Can Be Used to Study GO:0050731 positive regulation of peptidyl-tyrosine phosphorylation
Knockout
CRISPR knockout of a tyrosine kinase or adaptor gene can abolish specific phosphorylation events, providing causal evidence for its role in positive regulation. For example, knocking out EGFR in cancer cell lines reduces downstream AKT and ERK phosphorylation. Knockout models are also used to validate drug targets.
Point Mutation
Introducing point mutations such as kinase-dead or constitutively active variants allows precise dissection of catalytic activity versus scaffolding functions. For instance, a kinase-dead mutant can distinguish phosphorylation-dependent from independent roles. Point mutations in phosphotyrosine sites (Y to F) can test the importance of specific residues.
Knock-in
Knock-in of tagged or mutant alleles enables tracking of endogenous proteins and their phosphorylation status. For example, knock-in of a GFP-tagged kinase allows live-cell imaging of its localization and activation. Knock-in of disease-associated mutations such as JAK2 V617F recapitulates pathological phosphorylation.
Overexpression
Overexpression of a wild-type or mutant kinase can drive constitutive tyrosine phosphorylation, modeling oncogenic signaling. This approach is useful for identifying downstream effectors and testing inhibitors. However, overexpression may cause artifacts, so results should be validated with endogenous knock-in or knockout models.
How EDITGENE Supports positive regulation of peptidyl-tyrosine phosphorylation Research
Researchers studying positive regulation of peptidyl-tyrosine phosphorylation-related genes often need to determine whether a candidate gene is causally involved in a specific signaling event or disease phenotype. EDITGENE provides a comprehensive suite of CRISPR-based services to enable such functional validation, from knockout to precise point mutations and knock-in models.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of peptidyl-tyrosine phosphorylation research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| IL11 Knockout HEK293 Cell Line | EDJ-KQ479 | Human | 3589 | Details Get a Quote |
| IL6 Knockout HEK293 Cell Line | EDJ-KQ498 | Human | 3569 | Details Get a Quote |
| LIF Knockout HEK293 Cell Line | EDJ-KQ508 | Human | 3976 | Details Get a Quote |
| OSM Knockout HEK293 Cell Line | EDJ-KQ512 | Human | 5008 | Details Get a Quote |
| ANGPT4 Knockout HEK293 Cell Line | EDJ-KQ606 | Human | 51378 | Details Get a Quote |
| FGF10 Knockout HEK293 Cell Line | EDJ-KQ649 | Human | 2255 | Details Get a Quote |
| IL15 Knockout HEK293 Cell Line | EDJ-KQ1124 | Human | 3600 | Details Get a Quote |
| FGF7 Knockout HEK293 Cell Line | EDJ-KQ1195 | Human | 2252 | Details Get a Quote |
| ANGPT1 Knockout HEK293 Cell Line | EDJ-KQ1201 | Human | 284 | Details Get a Quote |
| CSPG4 Knockout HEK293 Cell Line | EDJ-KQ1941 | Human | 1464 | Details Get a Quote |
| TNK2 Knockout HEK293 Cell Line | EDJ-KQ6952 | Human | 10188 | Details Get a Quote |
| LACRT Knockout HEK293 Cell Line | EDJ-KQ10552 | Human | 90070 | Details Get a Quote |
| BANK1 Knockout HEK293 Cell Line | EDJ-KQ12512 | Human | 55024 | Details Get a Quote |
| THBS4 Knockout HEK293 Cell Line | EDJ-KQ14944 | Human | 7060 | Details Get a Quote |
| CD80 Knockout HEK293 Cell Line | EDJ-KQ17733 | Human | 941 | Details Get a Quote |
Displaying Records 1 To 15 Of 65 Records
- 1
- 2
- Next Page »
Frequently Asked Questions About positive regulation of peptidyl-tyrosine phosphorylation
What is GO:0050731?
GO:0050731 is the Gene Ontology term for positive regulation of peptidyl-tyrosine phosphorylation, describing any process that increases the addition of phosphate groups to tyrosine residues on proteins.
What genes are involved in positive regulation of peptidyl-tyrosine phosphorylation?
Key genes include EGFR, SRC, JAK2, STAT3, PTPN11, GRB2, and many others that encode kinases, phosphatases, and adaptor proteins.
How is peptidyl-tyrosine phosphorylation regulated?
It is regulated by the opposing activities of protein tyrosine kinases and phosphatases, as well as by adaptor proteins and feedback loops.
Why is tyrosine phosphorylation important in cancer?
Many cancers harbor mutations that constitutively activate tyrosine kinases, leading to uncontrolled proliferation and survival.
What methods are used to study tyrosine phosphorylation?
Common methods include phosphoproteomics, Western blotting, CRISPR screens, and bioinformatics analysis.
What is the role of phosphatases in this process?
Protein tyrosine phosphatases remove phosphate groups, counteracting positive regulation; their inhibition can enhance phosphorylation.
Can CRISPR be used to study tyrosine phosphorylation?
Yes, CRISPR knockout, point mutation, and knock-in models are widely used to dissect the function of specific genes in this process.
What diseases are associated with dysregulated tyrosine phosphorylation?
Cancer, inflammatory diseases, metabolic disorders, and some developmental syndromes.
How does network pharmacology help in this field?
It predicts interactions between drugs and tyrosine phosphorylation pathways, aiding in mechanism elucidation and drug discovery.
What services does EDITGENE offer for this research?
EDITGENE provides CRISPR knockout, point mutation, knock-in, overexpression cell models, library screening, and bioinformatics services.
Conclusion
GO:0050731, positive regulation of peptidyl-tyrosine phosphorylation, is a critical biological process that governs signal transduction and is implicated in numerous diseases. Understanding its regulators and mechanisms requires integrated approaches, from bioinformatics to CRISPR-based functional studies. EDITGENE offers a comprehensive toolkit to accelerate this research, enabling precise genetic models and data analysis.
References
- 1. Liu W et al.. 2023. Bioinformatics analysis of key biomarkers for bladder cancer.. Biomed Rep 18(2):14 PMID: 36643693
- 2. Xue J et al.. 2019. Identification of core differentially methylated genes in glioma.. Oncol Lett 18(6):6033-6045 PMID: 31788078
- 3. Wang Y et al.. 2020. Evaluation of the mechanism of Danggui-Shaoyao-San in regulating the metabolome of nephrotic syndrome based on urinary metabonomics and bioinformatics approaches.. J Ethnopharmacol 261:113020 PMID: 32592886
- 4. Peng H et al.. 2019. Comprehensive bioinformation analysis of methylated and differentially expressed genes in esophageal squamous cell carcinoma.. Mol Omics 15(1):88-100 PMID: 30706927
- 5. Lin H et al.. 2024. Integration of QTL and comprehensive analysis in the circulating inflammatory cytokines for pan-cancer.. BMC Cancer 24(1):1007 PMID: 39138392
- 6. He W et al.. 2024. Integrated approach of network pharmacology, molecular docking, and clinical observations in evaluating the efficacy and safety of Bufei Huoxue capsules for pulmonary hypertension associated with chronic obstructive pulmonary disease.. Pulm Circ 14(3):e12414 PMID: 39035784
- 7. Li X et al.. 2021. Exploration in the mechanism of fucosterol for the treatment of non-small cell lung cancer based on network pharmacology and molecular docking.. Sci Rep 11(1):4901 PMID: 33649481
- 8. Patel H et al.. 2026. Design, synthesis and biological evaluation of some imidazo[1,2-a]pyridine derivatives as anti-tubercular agents: an in silico - in vitro approach.. J Biomol Struct Dyn 44(1):202-219 PMID: 39663643
